{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T10:37:53Z","timestamp":1787999873808,"version":"build-2784847793"},"reference-count":11,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,6,1]]},"DOI":"10.2169\/internalmedicine.8387-21","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T22:11:00Z","timestamp":1635199860000},"page":"1739-1742","source":"Crossref","is-referenced-by-count":16,"title":["Lambert-Eaton Myasthenic Syndrome Caused by Atezolizumab in a Patient with Small-cell Lung Cancer"],"prefix":"10.2169","volume":"61","author":[{"given":"Eiji","family":"Kunii","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Thoracic Oncology Center, Nagoya City University West Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sota","family":"Owaki","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Thoracic Oncology Center, Nagoya City University West Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Thoracic Oncology Center, Nagoya City University West Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misuzu","family":"Yoshihara","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Thoracic Oncology Center, Nagoya City University West Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Yamaba","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Thoracic Oncology Center, Nagoya City University West Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Takakuwa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Thoracic Oncology Center, Nagoya City University West Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanari","family":"Toyoda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nagoya City University West Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Akita","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Thoracic Oncology Center, Nagoya City University West Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 10: 1098-1107, 2011.","DOI":"10.1016\/S1474-4422(11)70245-9"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Horn L, Mansfield AS, Szczesna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379: 2220-2229, 2018.","DOI":"10.1056\/NEJMoa1809064"},{"key":"3","unstructured":"3. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase3 trial. Lancet 394: 1929-1939, 2019."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. M\u00f6hn N, Beutel G, Gutzmer R, Ivanyi P, Satzger I, Skripulets T. Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy - review of the literature and future outlook. J Clin Med 8: 1777, 2019.","DOI":"10.3390\/jcm8111777"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Nakatani Y, Tanaka N, Enami T, Minami S, Okazaki T, Komuta K. Lambert-Eaton myasthenic syndrome caused by nivolumab in a patient with squamous cell lung cancer. Case Rep Neurol 10: 346-352, 2018.","DOI":"10.1159\/000494078"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Agrawal K, Agrawal N. Lambert-Eaton myasthenic syndrome secondary to nivolumab and ipilimumab in a patient with small-cell lung cancer. Case Rep Neurol Med 2019: 5353202, 2019.","DOI":"10.1155\/2019\/5353202"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Gill A J, Gandhy S, Lancaster E. Nivolumab-associated Lambert-Eaton myasthenic syndrome and cerebellar dysfunction in a patient with a neuroendocrine tumor. Muscle Nerve 63: E18-E21, 2020.","DOI":"10.1002\/mus.27141"},{"key":"8","unstructured":"8. Krishnan GS, Wilson WA. Immunotherapy related myasthenia gravis and Lambert Eaton syndrome case reports and review of literature. J Immunother 3: 007, 2020."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Titulaer MJ, Wirtz PW, Willems LN, van Kralingen KW, Smitt PA, Verschuurenn JJ. Screening of small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol 26: 4276-4281, 2008.","DOI":"10.1200\/JCO.2008.17.5133"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kao JC, Liao B, Markovic SN, et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol 74: 1216-1222, 2017.","DOI":"10.1001\/jamaneurol.2017.1912"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neural 17: 893-902, 2010.","DOI":"10.1111\/j.1468-1331.2010.03019.x"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/11\/61_8387-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T03:31:40Z","timestamp":1654313500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/11\/61_8387-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":11,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8387-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,1]]},"article-number":"8387-21"}}